Rapport Therapeutics Soars 30.15% on Drug Data Hype

On September 8, 2025, Rapport Therapeutics (NASDAQ:RAPP) surged 30.15% in pre-market trading, marking a significant rise in its stock price.

Rapport Therapeutics' stock price experienced a notable surge following the announcement that the company would release new data on its drug, RAP-219. This development has sparked investor interest and optimism about the potential of the drug, leading to a substantial increase in the company's stock value.

The upcoming data release is expected to provide crucial insights into the efficacy and safety of RAP-219, which has been a key focus for Rapport Therapeutics. Investors are eagerly awaiting the results, as positive data could further boost the company's market position and attract more investment.